תשאלו אותנו הכל
Gals Bio is pioneering a new category in women’s health and wellness called Fem-Wearables. Our first product within this category, Tulipon, currently undergoing clinical testing, will empower women experiencing abnormal bleeding, those with BRCA gene mutations, or a family history of cancer to easily collect their menstrual effluents and send them to a lab for liquid biopsy analysis. This innovative approach enables very early detection of potential malignancies in the reproductive system, offering a breakthrough in fertility organ cancer screening and shifting the paradigm of women’s health diagnostics and treatment.
Women’s personalized health and wellness needs remain largely unmet. In 2024, approximately one million women were diagnosed with cancer, with 300,000 succumbing to the disease. Despite advances in medicine, diagnostics continue to be late, painful, inaccurate, expensive, and difficult to access. This alarming reality is even more frustrating when considering that vaginal secretions—and particularly menstrual blood—are rich, non-invasive sources of biomarkers that can provide early, accessible, and highly informative insights into women’s health and wellness. Yet, this potential remains vastly underutilized, leaving millions of women without the preventive and diagnostic tools they need.
Tulipon is an innovative vaginal device, combined with a dedicated smartphone app, that enables women—for the first time ever—to easily, accurately, and reliably analyze vaginal secretions from home at an early stage. This groundbreaking solution empowers women with early diagnostics and health screening, enhancing proactive care and well-being.
Hilla Shaviv
CEO at Gals Bio Ltd
קצת עליי:
אנחנו פתחנו ענף חדש ברפואת נשים אשר מאפשר...
קראו עוד >>